Fig. 2From: Deciphering tumor-infiltrating dendritic cells in the single-cell eraDC signatures of tumorigenesis and progression. The proportion of pDCs increases during tumorigenesis, accompanied by a decrease in cDC2s and a downregulation of ICOSL. LAMP3+ DCs exhibit elevated expressions of immune checkpoint molecules CD274, PDCD1LG2, and IDO1. As tumors progress, the abundance of cDC1/2 and pDCs decreases, while LAMP3+ DCs become more abundant. In recurrent or metastatic tumors, LAMP3+ DCs interact with tumor cells via CD274/CD80 and CTLA4/CD80, suppressing T-cell activation. moDCs exhibit a signature associated with angiogenesis. Various DC subpopulations are present at different stages of tumors. The figure illustrates subpopulations that undergo significant quantitative or functional changes during tumor developmentBack to article page